Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

TRYP Therapeutics Inc. (C:TRYP)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: c/o Pushor Mitchell LLP
301 - 1665 Ellis Street
KELOWNA BC V1Y 2B3
Tel: N/A
Website: https://tryptherapeutics.com
IR: See website
Key People
N/A    
Business Overview
Tryp Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Company's lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The Company's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience.
Financial Overview
For the three months ended 30 November 2023, Tryp Therapeutics Inc revenues was not reported. Net loss decreased 29% to C$1.2M. Lower net loss reflects Research and development decrease of 73% to C$260K (expense), Share-based payments decrease of 85% to C$28K (expense), Interest income increase from C$1K to C$3K (income). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01.
Reporting Currency: Canadian Dollars
Enterprise value: $4.13M as of Nov 30, 2023
Annual revenue (TTM): $0.00M as of Nov 30, 2023
EBITDA (TTM): -$4.06M as of Nov 30, 2023
Net annual income (TTM): -$4.79M as of Nov 30, 2023
Free cash flow (TTM): -$3.63M as of Nov 30, 2023
Net Debt Last Fiscal Year: $2.95M as of Nov 30, 2023
Shares outstanding: 96,419,347 as of Nov 30, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization